Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Pfizer (NYSE: PFE) and Astellas announced final Phase 3 EMBARK results showing that XTANDI plus leuprolide reduced the risk of death by 40.3% (HR 0.597; 95% CI 0.444-0.804; p=0.0006) versus leuprolide alone in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.
The 8-year overall survival was 78.9% with XTANDI plus leuprolide vs 69.5% with leuprolide. Median follow-up was ~94 months. XTANDI monotherapy showed a numerical but not statistically significant OS improvement (HR 0.83; p=0.1867). Safety was consistent with prior analyses; common adverse events included hot flashes, fatigue and gynecomastia.
Pfizer (NYSE: PFE) reported updated Phase 2 PHAROS results for BRAFTOVI + MEKTOVI in BRAF V600E-mutant metastatic non-small cell lung cancer. In treatment-naïve patients median overall survival was 47.6 months (95% CI 31.3, NE) after a median follow-up of 52.3 months; previously treated patients had median OS 22.7 months after 48.2 months follow-up. Four-year OS rates were 49% (treatment-naïve) and 31% (previously treated). The ORR was 75% (treatment-naïve) and 46% (previously treated). Safety was consistent with prior data; most common TRAEs ≥30% included nausea, diarrhea, fatigue and vomiting. Data presented at ESMO 2025 and published in Journal of Clinical Oncology.
Pfizer (NYSE: PFE) and Astellas announced positive Phase 3 EV-303 (KEYNOTE-905) results for PADCEV plus KEYTRUDA given before and after surgery in cisplatin-ineligible muscle-invasive bladder cancer.
Key results: EFS HR 0.40 (60% risk reduction; median EFS not reached vs 15.7 months), OS HR 0.50 (50% risk reduction; median OS not reached vs 41.7 months), pCR 57.1% vs 8.6%. Two-year EFS 74.7% vs 39.4%; two-year survival 79.7% vs 63.1%.
Safety consistent with known profile; grade ≥3 AEs higher in combination arm. Regulatory discussions planned.
ViiV Healthcare (PFE shareholder) reported 96-week PASO DOBLE results showing Dovato (dolutegravir/lamivudine) is non-inferior to Biktarvy (bictegravir/emtricitabine/TAF) in maintaining virological suppression in 553 virologically suppressed adults who switched regimens.
Key findings: risk difference for HIV-1 RNA ≥50 copies/mL was –0.7% (95% CI –2.1 to 0.7). Dovato had significantly less weight gain (mean difference 1.52kg, 95% CI 0.74–2.29) and fewer drug-related adverse events (7.6% vs 13.4%, p=0.025) through 96 weeks. No resistance was observed in cases of virological failure.
ViiV Healthcare (PFE) reported initial CLARITY Phase I crossover data showing single-dose cabotegravir (CAB LA) injections were more acceptable and better tolerated than lenacapavir (LEN) injections in 63 HIV‑negative adults (data presented 15 Oct 2025).
Key findings: 69% rated CAB LA “totally or very acceptable” vs 48% for LEN (post hoc p=0.019); 90% of participants and 86% of healthcare providers preferred CAB LA; LEN produced 4.4× more injection‑site reactions (538 vs 123).
Pfizer (NYSE: PFE) reported positive topline Phase 3 results from the HER2CLIMB-05 trial on October 14, 2025: first-line maintenance treatment adding TUKYSA (tucatinib) to trastuzumab plus pertuzumab met the primary endpoint with a statistically significant improvement in progression-free survival (PFS) by investigator assessment.
The company said the combination was tolerable with a safety profile consistent with known profiles of each therapy. Results will be presented at a future medical congress and discussed with regulatory authorities. TUKYSA remains approved in later-line settings but is not currently approved for first-line treatment in the United States.
Pfizer (NYSE: PFE) will present research across its infectious disease portfolio at IDWeek 2025 in Atlanta, October 19–22, 2025. Pfizer will feature data in 46 abstracts, including oral, late-breaking and poster sessions on COVID-19, RSV, pneumococcal disease, Lyme, meningococcal disease and other bacterial and viral infections. Presentations include real-world vaccine effectiveness analyses, clinical subanalyses and epidemiology studies across multiple programs.
The program lists session dates/times and directs readers to full prescribing information for referenced vaccines and therapeutics.
Pfizer (NYSE: PFE) announced a $0.43 per-share quarterly cash dividend for fourth-quarter 2025. The dividend is payable December 1, 2025 to shareholders of record at the close of business on November 7, 2025. This payment will mark the 348th consecutive quarterly dividend paid by Pfizer, continuing the company’s long track record of returning cash to shareholders.
ViiV Healthcare (majority owned by GSK; Pfizer ticker PFE is a shareholder) will present >60 abstracts at EACS (Oct 15-18, 2025) and IDWeek (Oct 19-22, 2025). Key highlights include initial phase I CLARITY data comparing single-dose cabotegravir long-acting (CAB LA) and lenacapavir (LEN) injections (63 HIV-negative adults), a meta-analysis of 26 studies >7,000 people on CAB+RPV LA, 96-week PASO DOBLE results showing virological outcomes for DTG/3TC vs BIC/FTC/TAF, four-year OPERA cohort data on CAB+RPV LA persistence, and phase IIb EMBRACE safety/tolerability data for the N6LS antibody with CAB LA.
Astellas Pharma will present ten abstracts at the European Society for Medical Oncology (ESMO) congress from October 17-21, 2025. The presentations include significant data from their oncology portfolio, highlighted by the EV-303 trial (KEYNOTE-905) results in muscle-invasive bladder cancer, which earned a prestigious Presidential Symposium slot.
Key presentations include final survival data for XTANDI in non-metastatic hormone-sensitive prostate cancer, long-term follow-up data from EV-302 examining enfortumab vedotin with pembrolizumab in urothelial cancer, and first clinical data for their investigational CLDN18.2-targeted bispecific T cell engager ASP2138 in solid tumors.